Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
1
Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for sodium iodide (131i), the scientific conclusions are as follows: Incidences of severe hyponatraemia have been reported in thyroid cancer patients undergoing radioactive iodine therapy. The mechanism described in the scientific literature is multifactorial: hypothyroidism due to thyroid hormone replacement withdrawal prior to the radioactive iodine (RAI) treatment, prolonged low-iodine (low-sodium) diet, excessive hydration or use of thiazide diuretics. Although hyponatraemia has not been regarded as a direct adverse drug reaction of sodium iodide (131i), in a large retrospective study severe hyponatremia appeared to occur more frequently after RAI therapy. Severe hyponatraemia may result in life-threatening complications such as brain oedema and demyelination. Several publications recommend monitor sodium concentration especially in elderly patients undergoing RAI therapy. Although sodium iodide (131i) itself does not directly cause the hyponatremia, the instructions in the SmPC to increase efficacy (withdrawal thyroid hormone, low iodine diet) as well as those to decrease radiation exposure (strong hydration) do contribute to the phenomenon in this specific patient group and therefore a warning is considered necessary in the product information. Potentially life-threatening consequences of severe hyponatraemia may be preventable when healthcare professionals identify this rare side effect and initiate prompt intervention. The CMDh agrees with the scientific conclusions made by the PRAC.
Grounds for the variation to the terms of the Marketing Authorisation(s) On the basis of the scientific conclusions for sodium iodide (131i) the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing sodium iodide (131i) is unchanged subject to the proposed changes to the product information. The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing sodium iodide (131i) are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that such marketing authorisations are varied accordingly.
2
Annex II Amendments to the product information of the nationally authorised medicinal product(s)
3
Amendments to be included in the relevant sections of the Product Information (new text underlined and in bold, deleted text strike through)
Summary of Product Characteristics
Section 4.4
A warning should be added as follows: Hyponatraemia: Serious manifestations of hyponatraemia have been reported after sodium iodide [131I] therapy in elderly patients who have undergone total thyroidectomy. Risk factors include older age, female sex, use of thiazide diuretics and hyponatraemia at the start of sodium iodide [131I] therapy. Regular serum electrolytes measurements shall be considered for these patients.
Package Leaflet
Section 2
Warnings and precautions Low sodium blood levels have been observed in elderly patients who have had their thyroid removed. This event is most likely to occur in women and in patients taking medicines that increase the amount of water and sodium that is excreted in the urine (diuretics, such as hydrochlorothiazide). If you are included in some of these groups, your doctor may perform regular blood tests to check the amount of electrolytes (e.g. sodium) in your blood.
4
Annex III Timetable for the implementation of this position
5
Timetable for the implementation of this position
Adoption of CMDh position:
November 2017 CMDh meeting
Transmission to National Competent Authorities
23 December 2017
of the translations of the annexes to the position: Implementation of the position by the Member
21 February 2018
States (submission of the variation by the Marketing Authorisation Holder):
sodium iodide (131i): CMDh Scientific conclusions and grounds for the ...
Dec 23, 2017 - 2. Scientific conclusions. Taking into account the PRAC Assessment Report on the PSUR(s) for sodium iodide (131i), the scientific conclusions are as follows: ... do contribute to the phenomenon in this specific patient group and therefore a warning is considered necessary in the product information.
Jan 27, 2018 - Taking into account the PRAC Assessment Report on the PSUR(s) for cefuroxime sodium (except for ... cefuroxime sodium (except for intracameral use) is unchanged subject to the proposed changes to the product information. The CMDh reach
Dec 22, 2016 - Taking into account the PRAC Assessment Report on the PSUR(s) for granisetron ... Annex III. Timetable for the implementation of this position ...
Jun 9, 2018 - Based on a comprehensive review of âparaesthesiaâ, including ... of hypersensitivity reactions to chrysanthemums including literature ...
Aug 5, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for ... for the variation to the terms of the Marketing Authorisation(s) ... Page 3 ...
Jun 9, 2018 - peak toxicity and prolonged recovery when compared to immediate-release (IR) quetiapine overdose: a retrospective cohort study. Clinical ...
Nov 25, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for saccharomyces boulardii, the scientific ... patients is considered changed and an update of the product information is warranted. ... relevant sections of the SmPC (sect
Jun 4, 2017 - Grounds for the variation to the terms of the Marketing Authorisation(s). On the basis of the scientific conclusions for finasteride the CMDh is of ...
Mar 10, 2018 - trace residue from the manufacturing process), or to any of the excipients., or The the stopper of the glass vial with Actilyse powder which contains natural rubber (a derivative of latex). which may cause allergic reactions. No sustai
Dec 27, 2017 - for anxiety in one case and taking into account the listedness of these adverse reactions in the product information of other progestin only medicinal products, the lead member state considers that anxiety and depression should be incl
Nov 25, 2017 - Allergic reactions the signs of which may include difficulty in breathing, dizziness, collapsing or losing consciousness, swelling of your face, lips ...
27 Jan 2018 - Taking into account the PRAC Assessment Report on the PSUR(s) for lanthanum, the scientific ... this PSUR, the PRAC considers that the product information of lanthanum containing medicinal products should be ... Amendments to the produc
Oct 28, 2017 - Scientific conclusions. Taking into account the PRAC Assessment Report on the PSUR(s) for quinine, the scientific conclusions are as follows: Atrioventricular block ... The PRAC considers that the above information is relevant and ther
Taking into account the PRAC Assessment Report on the PSUR(s) for ivermectin (topical use), the scientific conclusions are as follows: During the reporting period, ... Amendments to be included in the relevant sections of the Product Information (new
Nov 26, 2016 - Taking into account the PRAC Assessment Report on the PSUR(s) for gabapentin, ... Annex III. Timetable for the implementation of this position ...
Mar 11, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) ... 3. Grounds for the variation to the terms of the Marketing Authorisation(s).
Jan 28, 2017 - Therefore, in view of the data presented in the reviewed PSUR(s), the ... The CMDh reaches the position that the marketing authorisation(s) of ...
Due to the existing structural homology between oxytocin and latex, latex allergy/intolerance may be an important predisposing risk factor for anaphylaxis.
27 Jan 2018 - Taking into account the PRAC Assessment Report on the PSUR(s) for glucosamine, the scientific ... insufficient information to conclude on a mechanism for an interaction between glucosamine and coumarin ... the product information of med
28 Oct 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for diacerein, the scientific ... Based on the information presented in this PSUR, PRAC considered that section 4.8 of the Summary of. Product ... Amendments to be included i
Nov 25, 2017 - Taking into account the PRAC Assessment Report on the PSUR(s) for bilastine, the scientific conclusions are as follows: During the reporting interval a ... hypersensitivity reactions should be included in the product information for bi
Jun 9, 2018 - Amendments to be included in the relevant sections of the Product Information (new text underlined and in bold, deleted text strike through).
Mar 11, 2017 - monitoring of immunosuppressant tacrolimus (sirolimus and cyclosporine) in presence of the concomitant administration of nicardipine to ...
Mar 12, 2018 - If a patient has a deficiency or is completely lacking this enzyme an adequate analgesic effect may not be obtained. Estimates indicate that up to 7% of the Caucasian population may have this deficiency. However, if the patient is an u